Molecularly integrated risk scores in patients with ET and PV
| . | Essential thrombocythemia . | Polycythemia vera . | |
|---|---|---|---|
| Characteristic . | Revised IPSET . | MIPSS-ETa . | MIPSS-PVa . |
| Age, y | >60 | >60 (4) | >67 (2) |
| History of thrombosis | Yes | — | Yes (1) |
| JAK2 V617F | Yes | — | — |
| White blood cell count | — | ≥11 × 109/L [1] | ≥15 × 109/L (1) |
| Adverse mutation | — | SRSF2, SF3B1, U2AF1, TP53 [2] | SRSF2 [3] |
| Male sex | — | Yes [1] | — |
| Thrombosis risk group (rate % patients/y) | Risk group [score]: median survival (y) | ||
| Categories | Very low: no thrombosis history, age ≤60 y, JAK2WT Low: no thrombosis history, age ≤60 y, JAK2 V617F Intermediate: no thrombosis history, age >60 y, JAK2WT High: thrombosis history or age >60 y with JAK2 V617F | Low [0-1]: 34.4 Intermediate [2-5]: 14.1 High [≥6]: 7.9 | Low [0-1]: 24.0 Intermediate [2-3]: 13.1 High [≥4]: 3.2 |
| . | Essential thrombocythemia . | Polycythemia vera . | |
|---|---|---|---|
| Characteristic . | Revised IPSET . | MIPSS-ETa . | MIPSS-PVa . |
| Age, y | >60 | >60 (4) | >67 (2) |
| History of thrombosis | Yes | — | Yes (1) |
| JAK2 V617F | Yes | — | — |
| White blood cell count | — | ≥11 × 109/L [1] | ≥15 × 109/L (1) |
| Adverse mutation | — | SRSF2, SF3B1, U2AF1, TP53 [2] | SRSF2 [3] |
| Male sex | — | Yes [1] | — |
| Thrombosis risk group (rate % patients/y) | Risk group [score]: median survival (y) | ||
| Categories | Very low: no thrombosis history, age ≤60 y, JAK2WT Low: no thrombosis history, age ≤60 y, JAK2 V617F Intermediate: no thrombosis history, age >60 y, JAK2WT High: thrombosis history or age >60 y with JAK2 V617F | Low [0-1]: 34.4 Intermediate [2-5]: 14.1 High [≥6]: 7.9 | Low [0-1]: 24.0 Intermediate [2-3]: 13.1 High [≥4]: 3.2 |
Values within brackets indicate the variable's rank.